Specializing in RNA medicines, Arcturus Therapeutics focuses on diseases with high unmet needs.
Their central product is a proprietary technology known as "LUNAR"(Lipid-enabled and Unlocked
Nucleomonomer Agent modified RNA). "LUNAR" is a delivery system that consists of a combination of RNAs and gene editing tools.
Arcturus in collaboration with Duke-National University of Singapore is developing an RNA based prophylactic vaccine to prevent COVID19 coronavirus infection.
The LUNAR-COVID19 combines Arcturus' self-replicating RNA STARR™ Technology with their LUNAR® RNA medicine delivery technology to develop a prophylactic vaccine against SARS-CoV-19. The combination of these two technologies results in (1) a RNA vaccine that can be produced more rapidly than conventional adjuvanted protein based vaccines, (2) a dramatic reduction in the RNA dose required to elicit a protective immune response, and (3) an increase in the duration of antigen expression potentially yielding protective immunity from SARS-CoV-19 with a single dose.